Avelumab and Merkel Cell Carcinoma Prognosis: Is the Disease Permanent?

From General Health to Occupational Exposure

For decades, public health communication has centered on general wellness principles—balanced nutrition, routine screening, and lifestyle factors that support long-term vitality. This legacy framework, while valuable for broad populations, often assumes that health risks are uniformly distributed and primarily driven by individual choices. In mass production environments, however, the calculus shifts: workers face repeated, involuntary exposures to substances that may carry distinct biological consequences. One such substance is Avelumab, a therapeutic monoclonal antibody used in oncology, which has entered industrial settings through pharmaceutical manufacturing and related supply chains. Occupational exposure to Avelumab, even at trace levels, raises questions that general health guidance does not address. Specifically, workers handling this compound may wonder about downstream risks, including the potential for malignancies such as Merkel cell carcinoma. The transition from a general health context to this occupational concern requires acknowledging that exposure scenarios differ fundamentally: what is a controlled therapeutic dose for a patient becomes an uncontrolled variable for a production worker. Thus, the pivot from legacy health information to targeted occupational risk assessment is not merely a change in topic but a shift in analytical lens—from population-level advice to exposure-specific vigilance.

Understanding Avelumab and Its Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This raises critical questions about the permanence of MCC in patients treated with avelumab and the prognosis for those who become refractory to this agent.

Prognosis and Permanence of Merkel Cell Carcinoma

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and it carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). The clinical presentation typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often on the head, neck, or extremities. Diagnosis is confirmed by histopathology and immunohistochemistry, with characteristic neuroendocrine markers. The aggressive nature of MCC means that even with treatment, the disease may not be permanently eradicated. For patients who respond to avelumab, durable responses have been reported, but the term "permanent" is not supported by the evidence. The JAVELIN Merkel 200 trial showed ongoing responses in some patients, but long-term follow-up data are limited, and the possibility of late recurrence or progression remains. The mechanistic pathway linking avelumab to MCC is indirect: avelumab is a treatment for MCC, not a cause. It works by blocking PD-L1 on tumor cells, thereby reactivating T-cell-mediated immune responses against the cancer. However, immune checkpoint inhibitors, including avelumab, can cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that while avelumab can be effective, it also carries risks of immune-mediated complications that may affect prognosis.

Management of Avelumab-Refractory Merkel Cell Carcinoma

For patients who become refractory to avelumab, prognosis is poor, as efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). However, emerging evidence suggests that combination therapy with ipilimumab plus nivolumab may offer benefit in avelumab-refractory MCC. In a multicenter study from Germany, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab/nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A separate retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC also reported clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). These findings indicate that while avelumab-refractory MCC is a serious condition, alternative immunotherapeutic strategies may improve outcomes, though they do not guarantee permanence of disease control. The adequacy of warnings regarding avelumab and MCC is addressed in the prescribing information and clinical guidelines. Avelumab is approved specifically for metastatic MCC, and its use is associated with known risks of irAEs, including pneumonitis, hepatitis, colitis, endocrinopathies, and infusion-related reactions. The evidence does not suggest that avelumab causes MCC; rather, it is a treatment for the disease. However, the risk of progression or lack of response is well-documented, with approximately 50% of patients not achieving durable benefit (https://pubmed.ncbi.nlm.nih.gov/35877101/). Prognosis-related considerations for affected patients include the aggressive nature of MCC, the possibility of avelumab-refractoriness, and the potential for salvage therapy with combination ICI regimens. The timeline between exposure to avelumab and documented harm is variable: irAEs can occur weeks to months after initiation, while disease progression may be evident at the first restaging scan or later. In the case of sarcoidosis reactivation, hypercalcemia developed during treatment and resolved with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the timeline to subsequent therapy and response is not well-defined, but the ADOREG registry study provides evidence of benefit from ipilimumab plus nivolumab in this setting (https://pubmed.ncbi.nlm.nih.gov/36450381/). In summary, Merkel cell carcinoma treated with avelumab is not necessarily permanent. While avelumab can induce durable responses in a subset of patients, the disease remains aggressive, and many patients experience progression. The prognosis for avelumab-refractory MCC is guarded, but combination immunotherapy offers a potential salvage option. The evidence does not support the notion that avelumab causes MCC; rather, it is a therapeutic agent with established efficacy and known immune-related risks. Patients and clinicians should be aware of the high rates of recurrence and mortality associated with MCC, the possibility of irAEs during avelumab therapy, and the availability of subsequent treatment options for refractory disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It works by blocking PD-L1 on tumor cells to reactivate immune responses against the cancer (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Is Merkel cell carcinoma permanent after avelumab treatment?

Merkel cell carcinoma is not necessarily permanent after avelumab. While some patients achieve durable responses, the disease remains aggressive with high recurrence rates. Approximately 50% of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

What are the treatment options for avelumab-refractory Merkel cell carcinoma?

Combination immunotherapy with ipilimumab plus nivolumab has shown benefit in avelumab-refractory MCC, with response rates up to 62% in some studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.